Table 1 Baseline characteristics of study participants.

N

34

25

25

Age (year)

52.62 ± 6.68

56.24 ± 11.7

51.08 ± 8.58

Male

16 (47.1)

12 (48)

13(52)

SBP (mmHg)

119.63 ± 18.69

138.72 ± 17.37*

136.04 ± 17.92#

DBP (mmHg)

77.50 ± 12.00

81.96 ± 9.01

79.32 ± 10.08

CKD stage

3–4 (eGFR 15–59)

0

10

13

5 (eGFR < 15)

0

15

12

Primary disease

CGN

0

9

16

DM

0

5

6

HT

0

7

0

SLE

0

1

0

AP

0

1

0

DPKD

0

0

1

Other

0

2

2

Colonic dialysis duration (year)

–

3.26 ± 2.52(0.6–8.5)

–

Colonic dialysis frequency (times per week)

–

3.33 ± 1.39(1–7)

–

Laboratory parameters

Hb (g/L)

141.97 ± 14.35

107.75 ± 20.87*

96.92 ± 25.50^#

ALB(g/L)

46.06 ± 2.50

39.67 ± 5.59*

38.94 ± 8.00^#

LDL (mmol/L)

3.29 ± 0.69

3.00 ± 0.76

3.16 ± 0.77

TG (mmol/L)

1.57 ± 0.90

2.30 ± 1.38*

2.19 ± 1.45^#

TC (mmol/L)

5.27 ± 0.90

4.74 ± 1.18

5.06 ± 1.03

Glu (mmol/L)

5.98 ± 1.86

5.46 ± 1.29

6.36 ± 3.61

Urea (mmol/L)

5.29 ± 1.32

17.11 ± 6.93

16.37 ± 6.74

UA (mmol/L)

334.01 ± 80.22

431.18 ± 104.95*

443.14 ± 103.85^#

K (mmol/L)

–

4.52 ± 0.60

4.64 ± 0.71

Ca (mmol/L)

–

2.21 ± 0.15

2.20 ± 0.19

P (mmol/L)

–

1.41 ± 0.30

1.46 ± 0.50

Mg (mmol/L)

–

0.86 ± 0.15

0.84 ± 0.10

Qualitative determination of urinary protein

Negative

30

1

1

Microscale

3

3

0

Positive

1

21

24

Medications at baseline

Calcium channel-blockers

–

17

11

ACE inhibitors/ARBs

–

8

9

Beta-blockers

–

10

7

Diuretics

–

2

2

Iron agents

–

3

5

Phosphate binders

–

0

0

EPO

–

5

7

Anticoagulants

–

7

6

Lipid-lowering drugs

–

6

5

Antidiabetic drugs

–

4

4

Other BP-lowering drugs

–

6

1